Roberto Camerini

1.6k total citations
27 papers, 844 citations indexed

About

Roberto Camerini is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Roberto Camerini has authored 27 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Roberto Camerini's work include Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Inflammatory Bowel Disease (4 papers). Roberto Camerini is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Inflammatory Bowel Disease (4 papers). Roberto Camerini collaborates with scholars based in Italy, Switzerland and United States. Roberto Camerini's co-authors include Enrico Garaci, Jorgelina Coppa, Giorgio Parmiani, Matteo Giovanni Carrabba, Licia Rivoltini, Pramod K. Srivastava, Vincenzo Mazzaferro, Jonathan J. Lewis, Simona Piccirella and Baharak Khadang and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Gastroenterology.

In The Last Decade

Roberto Camerini

27 papers receiving 806 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roberto Camerini Italy 17 383 351 214 144 107 27 844
Chang Chun Ling Hong Kong 14 458 1.2× 404 1.2× 203 0.9× 114 0.8× 59 0.6× 20 1.0k
Tetsuro Okamoto Japan 17 241 0.6× 379 1.1× 144 0.7× 74 0.5× 116 1.1× 42 892
Seon-Ah Ha South Korea 14 304 0.8× 447 1.3× 180 0.8× 113 0.8× 36 0.3× 20 928
Nicole Faust Germany 14 559 1.5× 399 1.1× 132 0.6× 101 0.7× 79 0.7× 21 1.2k
Cesar F. Ortega-Cava Japan 15 403 1.1× 434 1.2× 179 0.8× 83 0.6× 117 1.1× 19 1.1k
Long Huang China 14 566 1.5× 358 1.0× 213 1.0× 153 1.1× 32 0.3× 44 1.3k
Eduardo Martı́nez-Naves Spain 20 589 1.5× 221 0.6× 99 0.5× 204 1.4× 65 0.6× 51 1.1k
Yongxue Yao United States 18 604 1.6× 504 1.4× 242 1.1× 118 0.8× 44 0.4× 30 1.4k
Guo‐Yun Chen United States 11 680 1.8× 434 1.2× 151 0.7× 76 0.5× 52 0.5× 25 1.1k
Ryan Oyer United States 9 432 1.1× 625 1.8× 225 1.1× 96 0.7× 122 1.1× 14 1.2k

Countries citing papers authored by Roberto Camerini

Since Specialization
Citations

This map shows the geographic impact of Roberto Camerini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Camerini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Camerini more than expected).

Fields of papers citing papers by Roberto Camerini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Camerini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Camerini. The network helps show where Roberto Camerini may publish in the future.

Co-authorship network of co-authors of Roberto Camerini

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Camerini. A scholar is included among the top collaborators of Roberto Camerini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Camerini. Roberto Camerini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2024). Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. European Journal of Cancer. 199. 113531–113531. 11 indexed citations
2.
Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654. 2 indexed citations
3.
Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745. 41 indexed citations
4.
Agrati, Chiara, Stefania Capone, Concetta Castilletti, et al.. (2021). Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. npj Vaccines. 6(1). 131–131. 7 indexed citations
5.
Danielli, Riccardo, Diana Giannarelli, Luana Calabrò, et al.. (2018). Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. Expert Opinion on Biological Therapy. 18(sup1). 77–83. 18 indexed citations
6.
Garaci, Enrico, Francesca Pica, Claudia Matteucci, et al.. (2015). Historical review on thymosin α1 in oncology: preclinical and clinical experiences. Expert Opinion on Biological Therapy. 15(sup1). 31–39. 26 indexed citations
7.
Camerini, Roberto & Enrico Garaci. (2015). Historical review of thymosin α 1 in infectious diseases. Expert Opinion on Biological Therapy. 15(sup1). 117–127. 42 indexed citations
8.
Scioli, Maria Giovanna, Maria Antonietta Stasi, Daniela Passeri, et al.. (2014). Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature. Clinical and Translational Gastroenterology. 5(3). e55–e55. 30 indexed citations
9.
Tuthill, Cynthia, et al.. (2012). Thymosin α1 continues to show promise as an enhancer for vaccine response. Annals of the New York Academy of Sciences. 1270(1). 21–27. 17 indexed citations
10.
Camerini, Roberto. (2012). Can we treat ulcerative colitis with nutritional supplements? author’s reply. Alimentary Pharmacology & Therapeutics. 35(4). 486–487. 1 indexed citations
11.
Ciancio, Alessia, Pietro Andreoné, S Kaiser, et al.. (2012). Thymosin alpha‐1 with peginterferon alfa‐2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. Journal of Viral Hepatitis. 19(s1). 52–59. 18 indexed citations
12.
Carraro, Gianni, A Naso, Emanuele Montomoli, et al.. (2011). Thymosin-alpha 1 (Zadaxin™) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria™) in hemodialyzed patients: A pilot study. Vaccine. 30(6). 1170–1180. 22 indexed citations
13.
Montomoli, Emanuele, et al.. (2011). Current adjuvants and new perspectives in vaccine formulation. Expert Review of Vaccines. 10(7). 1053–1061. 90 indexed citations
14.
DeRosa, Antonio P., et al.. (2010). The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 1194(1). 207–212. 17 indexed citations
15.
Camerini, Roberto, et al.. (2007). Thymosin β‐4 and Venous Ulcers. Annals of the New York Academy of Sciences. 1112(1). 407–412. 13 indexed citations
16.
Camerini, Roberto, et al.. (2007). Studies of Therapy with Thymosin α1 in Combination with Pegylated Interferon α2a and Ribavirin in Nonresponder Patients with Chronic Hepatitis C. Annals of the New York Academy of Sciences. 1112(1). 368–374. 8 indexed citations
17.
Rivoltini, Licia, Chiara Castelli, Matteo Giovanni Carrabba, et al.. (2003). Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells. The Journal of Immunology. 171(7). 3467–3474. 93 indexed citations
18.
Mazzaferro, Vincenzo, Jorgelina Coppa, Matteo Giovanni Carrabba, et al.. (2003). Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.. PubMed. 9(9). 3235–45. 187 indexed citations
19.
Zingarelli, Basilia, et al.. (1993). Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Inflammation Research. 39(3-4). 150–156. 58 indexed citations
20.
Camerini, Roberto, et al.. (1953). [Tomography as a research means of bladder walls].. PubMed. 22(5). 421–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chang Chun Ling Breakdown of academic impact, for papers by Tetsuro Okamoto Breakdown of academic impact, for papers by Seon-Ah Ha Breakdown of academic impact, for papers by Nicole Faust Breakdown of academic impact, for papers by Cesar F. Ortega-Cava Breakdown of academic impact, for papers by Long Huang Breakdown of academic impact, for papers by Eduardo Martı́nez-Naves Breakdown of academic impact, for papers by Yongxue Yao Breakdown of academic impact, for papers by Guo‐Yun Chen Breakdown of academic impact, for papers by Ryan Oyer
Rankless by CCL
2026